- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05365100
A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL
A Multicenter Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of BN102 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-cell Non-Hodgkin's Lymphoma (NHL)
Study Overview
Detailed Description
The study is divided into 2 phases. Phase1 dose escalation part will enroll 17-36 patients to evaluate safety and tolerance of BN102 in patients with relapsed/refractory (R/R) CLL/SLL and B-NHL to determine maximum tolerated dose and recommended phase2 dose(RP2D).
Phase 2 expansion part will enroll 72-138 patients and be conducted at the selected dose level to further evaluate the safety and tolerability of BN102,as well as preliminary efficacy in specific subtypes of lymphoma. Patients will be allocated into 6 lymphoma subgroup cohorts depends on whether their previous treatment with or without BTK inhibitors.
- Cohort 1: patients with mantle cell lymphoma (MCL) previously treated with BTK inhibitors
- Cohort 2: patients with MCL who have not previously received a BTK inhibitor
- Cohort 3: patients with CLL/SLL who have received prior BTK inhibitors
- Cohort 4: patients with CLL/SLL who have not received prior BTK inhibitors
- Cohort 5: other B-NHL patients who have received prior BTK inhibitors
- Cohort 6: other B-NHL patients who have not received prior BTK inhibitors
Patients will receive orally administrated BN102 twice daily under fasting status. Study drug will be administered in 28-day cycles until disease progression or unacceptable toxicity, death, ICF withdraw ect. Subjects may receive study drug in the inpatient or outpatient setting.
Study Type
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Yolin Pan
- Phone Number: +86 18616503777
- Email: yolin.pan@bionovapharma.com
Study Locations
-
-
-
Guangzhou, China
- Zhujiang Hospital of Southern Medical University
-
Contact:
- Sanfang Tu
-
Principal Investigator:
- Sanfang Tu
-
Nanning, China
- The First Affiliated School of Guangxi Medical University
-
Contact:
- Zhenfang Liu, Prof.
-
Principal Investigator:
- Zhenfang Liu, Prof.
-
Shanghai, China
- Shanghai Jiao Tong University School of Medicine, Ruijin Hospital
-
Contact:
- Weili Zhao, Prof.
-
Principal Investigator:
- Weili Zhao, Prof.
-
Suzhou, China
- The First Affiliated Hospital of Soochow University
-
Contact:
- Zhengming Jin, Prof.
-
Principal Investigator:
- Zhengming Jin, Prof.
-
Wuhan, China
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Contact:
- Liling Zhang, Prof.
-
Principal Investigator:
- Liling Zhang, Prof.
-
Zhengzhou, China
- Henan Oncology Hospital
-
Contact:
- Baijun Fang, Prof.
-
Principal Investigator:
- Baijun Fang, Prof.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
All of the following conditions must be met for subject enrollment:
- Have fully understood and voluntarily signed the informed consent form ;
- Age ≥ 18 years;
- In phase 1, subjects with histologically confirmed CLL/SLL or B-cell NHL who are relapsed/refractory or intolerable after at least 1 prior line of adequate therapy, and have no better treatment choice as assessed by the investigator;
- In Phase 2, the 6 cohorts had the following specific enrollment criteria and required further treatment:
- Cohort 1: histologically confirmed MCL, failure or intolerance to at least one prior treatment including BTK inhibitor;
- Cohort 2: histologically confirmed MCL, failure or intolerance to at least 1 prior standard of care (BTK inhibitors naive);
- Cohort 3: histologically confirmed CLL/SLL, failure or intolerance to at least 1 prior treatment including BTK inhibitor;
- Cohort 4: histologically confirmed CLL/SLL, failure or intolerance to at least 1 prior standard of care (BTK inhibitors naive);
- Cohort 5: histologically confirmed other B-NHL, failure or intolerance to at least 1 prior treatment including BTK inhibitor;
- Cohort 6: histologically confirmed other B-NHL, failure or intolerance to at least 1 prior standard of care (BTK inhibitors naive);
- In addition to CLL and WM, subjects must have at least one radiographically measurable lesion
- ECOG score 0-2;
- Male or female patients of childbearing potential must agree to use effective methods of contraception
Exclusion Criteria:
- Primary central nervous system lymphoma or lymphoma involving the central nervous system;
- Serological status reflects active viral hepatitis B (HBV) or viral hepatitis C (HCV) infection
- HIV infection;
- Abnormalities in hematology lab results
- Cardiac, hepatic, renal, and coagulation abnormalities
- Concomitant clinically significant systemic active infection uncontrollable after appropriate antibiotics or other treatment;
- Expected survival of no more than 24 weeks as judged by the investigator;
- Major surgery within 4 weeks prior to the first dose of study drug
- Required or received anticoagulant therapy (warfarin, or equivalent vitamin K antagonist, or direct thrombin inhibitor, or factor Xa inhibitor, etc.) within 7 days prior to the first dose of study treatment;
- Had undergone cell transplantation or chimeric antigen receptor T cell (CAR-T) therapy within 60 days prior to enrollment
- Combined with uncontrolled active immune cytopenia
- Previous treatment with non-covalently binding BTK inhibitors (e.g. LOXO-305, MK-1026, etc.);
- Pregnant (positive pregnancy test at screening) or lactating female patients;
- QTcF > 450 msec in male patients or QTcF > 470 msec in female patients or other significant ECG abnormalities as judged by the investigator;
- Toxicities due to prior antilymphoma therapy have not stabilized and have not recovered to ≤ Grade 1 (except for clinically insignificant toxicities such as alopecia, etc.);
- History of other malignancies within 5 years prior to enrollment, special cases must be discussed with the medical monitor;
- Prior systemic anti-tumor therapy or investigational therapy received less than 4 weeks or 5 half-lives (whichever is shorter) from the start of the planned study treatment;
- Use of strong CYP3A inhibitors or inducers and proton pump inhibitors within 1 week or 5 half-lives (whichever is shorter) before administration of the first study drug;
- History of acute myocardial infarction, unstable angina, stroke, intracranial hemorrhage or transient ischemic attack within 6 months prior to enrollment; New York Heart Association (NYHA) grade 3 and 4 congestive heart failure;
- Live viral vaccination within 28 days prior to the first dose of study drug;
- Unable to take oral drugs, or have severe gastrointestinal diseases that investigator believes that it may affect the absorption of the study drug;
- Insufficient compliance of patients participating in this clinical study as judged by the investigator;
- Any other disease or condition in the judgment of the investigator that the patient is not suitable for the study drug, or will affect the interpretation of the study results
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase1dose escalation
Phase1 Dose Escalation Multiple dose levels of BN102 to be evaluated; determination of MTD/Phase 2 recommended dose(RP2D)
|
oral tablets: BN102, BID
Other Names:
|
Experimental: Phase2 expansion in R/R MCL with BTK inhibitor treatment history
patients must have received at least one systemic treatment and failed or relapsed, patients previous treatment should with BTK inhibitor, approximate 12-23 patients this group
|
oral tablets: BN102, BID
Other Names:
|
Experimental: Phase2 expansion in R/R MCL without BTK inhibitor treatment history
patients must have received at least one systemic treatment and failed or relapsed, patients previous treatment should without BTK inhibitor, approximate 12-23 patients this group
|
oral tablets: BN102, BID
Other Names:
|
Experimental: Phase2 expansion in R/R CLL/SLL with BTK inhibitor treatment history
patients must have received at least one systemic treatment and failed or relapsed, patients previous treatment should with BTK inhibitor, approximate 12-23 patients this group
|
oral tablets: BN102, BID
Other Names:
|
Experimental: Phase2 Expansion in R/R CLL/SLL without BTK inhibitor treatment history
patients must have received at least one systemic treatment and failed or relapsed, patents previous treatment should without BTK inhibitor, approximate 12-23 patients this group
|
oral tablets: BN102, BID
Other Names:
|
Experimental: Phase2 Expansion in other R/R B-NHL with BTK inhibitor treatment history
patients must have received at least one systemic treatment and failed or relapsed, patents previous treatment should with BTK inhibitor, approximate 12-23 patients this group
|
oral tablets: BN102, BID
Other Names:
|
Experimental: Phase2 Expansion in other R/R B-NHL without BTK inhibitor treatment history
patients must have received at least one systemic treatment and failed or relapsed, patents previous treatment should without BTK inhibitor, approximate 12-23 patients this group
|
oral tablets: BN102, BID
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Adverse Events and Clinical Laboratory Abnormalities
Time Frame: 2 year
|
Phase1
|
2 year
|
To assess the preliminary anti-tumor activity of BN102 based on Overall response rate(ORR) assessed by the Investigator
Time Frame: 3 years
|
Phase2
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate(ORR) as assessed by the Investigator
Time Frame: 3 years
|
Phase1
|
3 years
|
Time to response(TTR) as assessed by the Investigator
Time Frame: 3 years
|
Phase1/2
|
3 years
|
Duration of response(DoR) as assessed by the Investigator
Time Frame: 3 years
|
Phase1/2
|
3 years
|
Progression-free survival(PFS) as assessed by the Investigator
Time Frame: 3 years
|
Phase1/2
|
3 years
|
Overall Survival(OS) as assessed by the Investigator
Time Frame: 3 years
|
Phase1/2
|
3 years
|
To characterized Maximum Plasma Concentration [Cmax] of BN102 by collecting and evaluating the serum at the protocol specified time points.
Time Frame: at the end of cycle1(each cycle is28days) and Cycle2 Day1
|
Phase1/2
|
at the end of cycle1(each cycle is28days) and Cycle2 Day1
|
To characterized Peak time(Tmax) of BN102 by collecting and evaluating the serum at the protocol specified time points.
Time Frame: at the end of cycle1(each cycle is28days) and Cycle2 Day1
|
Phase1/2
|
at the end of cycle1(each cycle is28days) and Cycle2 Day1
|
To characterized Clearance half-life (T1/2) of BN102 by collecting and evaluating the serum at the protocol specified time points.
Time Frame: at the end of cycle1(each cycle is28days) and Cycle2 Day1
|
Phase1/2
|
at the end of cycle1(each cycle is28days) and Cycle2 Day1
|
To characterized Area under the blood concentration-time curve (AUC0-t) of BN102 by collecting and evaluating the serum at the protocol specified time points.
Time Frame: at the end of cycle1(each cycle is28days) and Cycle2 Day1
|
Phase1/2
|
at the end of cycle1(each cycle is28days) and Cycle2 Day1
|
To characterized Clearance rate (CL/F) of BN102 by collecting and evaluating the serum at the protocol specified time points.
Time Frame: at the end of cycle1(each cycle is28days) and Cycle2 Day1
|
Phase1/2
|
at the end of cycle1(each cycle is28days) and Cycle2 Day1
|
To characterized apparent volume of distribution (Vd/F) of BN102 by collecting and evaluating the serum at the protocol specified time points.
Time Frame: at the end of cycle1(each cycle is28days) and Cycle2 Day1
|
Phase1/2
|
at the end of cycle1(each cycle is28days) and Cycle2 Day1
|
To characterized mean residence time (MRT) of BN102 by collecting and evaluating the serum at the protocol specified time points.
Time Frame: at the end of cycle1(each cycle is28days) and Cycle2 Day1
|
Phase1/2
|
at the end of cycle1(each cycle is28days) and Cycle2 Day1
|
Number of Participants with Adverse Events and Clinical Laboratory Abnormalities
Time Frame: 2 years
|
Phase2
|
2 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Weili Zhao, Prof., Shanghai Jiaotong University school of Medicine, Ruijin Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- BN102-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NHL
-
National Cancer Institute (NCI)Completed
-
Beijing Immunochina Medical Science & Technology...Unknown
-
Shengke Pharmaceuticals Pty LtdTerminatedLeukemia | NHLAustralia
-
Duke UniversityTerminated
-
EdiGene (GuangZhou) Inc.The First Affiliated Hospital of Henan University of Science and TechnologyActive, not recruitingRelapsed or Refractory B-cell Malignancy(NHL/ALL)China
-
Alexion PharmaceuticalsPortola PharmaceuticalsCompletedFollicular Lymphoma (FL/Indolent NHL) | Aggressive NHL (a NHL) | Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) | T-cell Lymphoma (PTCL and CTCL) | B-cell Non Hodgkin Lymphoma (NHL)United States
-
Calithera Biosciences, IncCompletedMultiple Myeloma | Non-Hodgkin's Lymphoma (NHL) | Waldenstrom's Macroglobulinemia (WM) | Other B-cell NHL Subtypes, Including WM | T-cell NHLUnited States
-
Gilead SciencesCompleted
-
Spectrum Pharmaceuticals, IncThe Leukemia and Lymphoma SocietyWithdrawn
-
Mundipharma Research LimitedTerminatedIndolent B-cell NHLAustralia, Slovakia